This is a phase III trial evaluating the effectiveness of targeted therapy (Pembrolizumab) plus chemotherapy (Gemcitabine/Cisplatin) to treat advanced or unresectable biliary tract carcinoma.
This trial is treating patients with Biliary Tract Carcinoma.
This is a systemic therapy.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A phase 3 randomised, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresctable biliary tract carcinoma
Patients eligible to participate in the trial will receive either intravenous infusion of pembrolizumab or a placebo on Day 1 of each 3-week cycle for 35 cycles, plus gemcitabine and cisplatin on Day 1 and 8 of each 3 week cycle. Gemcitabine will be received until unacceptable toxicity or disease progression and cisplatin will be received for up to 8 cycles.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More